Philip Bedford Consulting Ltd image

Philip Bedford was awarded a PhD in tumour biology from the University of Manchester in 1981 and thereafter undertook several post-doctoral research fellowships in Germany, USA and UK. In 1987 he joined what was then The Wellcome Foundation Limited (predecessor of GSK), undertaking a variety of clinical research and project leadership roles, including management of the European Clinical Oncology Department and International Project Leadership for the anti-cancer monoclonal antibodies Campath-1H® and 17-1A (Adjuqual®; formerly Panorex).

In 1997 he joined Peptide Therapeutics plc as Development Director, becoming Senior Vice President of Clinical Operations and Regulatory Affairs following Peptide’s merger with the US vaccine development company, OraVax, forming Acambis plc. During his 10 years with Acambis, Philip oversaw the submission of 2 Biologics Licence Applications (BLA) and 8 Investigational New Drug (IND) applications. Notable amongst his achievements was helping to take the world’s first cell culture-derived smallpox vaccine (ACAM2000) from laboratory to BLA submission in less than 4 years. The vaccine was subsequently approved by the FDA and is being used by the US Department of Defence to vaccinate troops.

For the last 10 years, Philip has provided consulting services for numerous clients ranging from start-up biotech companies to blue-chip pharmaceutical companies and he has gained a formidable reputation as one of the “go to” consultants for development advice for vaccines and biological products.

During more than 30 years in the pharmaceutical industry, Philip has overseen at least 100 clinical trials from Phase 1 to Phase 4 and has taken numerous product candidates into man for the first time.

Philip is a mentor for students from the University of Manchester.

Philip is author of more than 30 peer-reviewed scientific publications and speaks passable Italian and German.